Fact sheet: Variopartner SICAV SeBiOpp

Fund information

Fund name
Variopartner SICAV Sectoral Biotech Opportunities I USD
Fund company manager
Vontobel Asset Management S.A.
Fund type
SIB
Fund manager(s)
Mina Marmor
since 31/05/2016
Fund objective
While respecting the principle of risk diversification, the Sub-Fund's assets are primarily invested in shares, equity-like transferable securities, participation certificates etc. issued by companies worldwide which are active in the generics sector. No geographical restrictions apply re. specific countries or regions.
Benchmark
Nasdaq Biotech Index
Investment style
None
Investment method
Shares

Quick stats

1 Year return

44.77 %

1 Year rank in sector

1/30

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 142.8 m

FE Risk score

247

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    89.6%
  • Money Market
    3.5%
  • Sweden
    2%
  • Switzerland
    1.5%
  • Israel
    1.3%
  • Biotechnology/Medical
    83.5%
  • Pharmaceuticals
    13%
  • Money Market
    3.5%
  • US Equities
    89.6%
  • Money Market
    3.5%
  • Swedish Equities
    2%
  • Swiss Equities
    1.5%
  • Israeli Equities
    1.3%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund7.12 %7.34 %44.77 %0 %0 %
Sector3.73 %2.7 %14.98 %11.64 %96.5 %
Rank within sector2 / 313 / 311 / 30 / /
Quartile th1 st1 st1 st th th

Calendar performance

YTD-20182017201620152014
Fund1.96 %48.61 %-22.42 %0 %0 %
Sector3.38 %14.94 %-9.92 %7.24 %28.08 %
Rank within sector25 / 311 / 3028 / 30 / /
Quartile th4 th1 st4 th th th

Price movement

52 week high10.62
52 week low7.08
Current bid price0
Current offer price0
Current mid price10.38

Holdings by region

  • 89.6% USA
  • 3.5% Money Market
  • 2% Sweden
  • 1.5% Switzerland
  • 1.3% Israel
  • 1.1% France
  • 1% Canada

Holdings by sector

  • 83.5% Biotechnology/Medical
  • 13% Pharmaceuticals
  • 3.5% Money Market

Holdings by asset type

  • 89.6% US Equities
  • 3.5% Money Market
  • 2% Swedish Equities
  • 1.5% Swiss Equities
  • 1.3% Israeli Equities
  • 1.1% French Equities
  • 1% Canadian Equities

Individual holdings

  • 6.7% AMICUS THERAPEUTICS
  • 5.2% CELGENE CORP
  • 4.7% LA JOLLA PHARMACEUTICAL CO
  • 4.6% AERIE PHARMACEUTICALS INC
  • 4.5% ACCELERON PHARMA INC
  • 4.2% ACADIA PHARMACEUTICALS INC
  • 4.2% PORTOLA PHARMACEUTICALS INC
  • 4% BIOMARIN PHARMACEUTICAL
  • 4% VERTEX PHARMACEUTICALS INC
  • 3.8% SAREPTA THERAPEUTICS INC